Showing results (51-60 of 142) with videos related to
Sort By:
Pageof 15
Pediatric Blood & Cancer|November 6, 2008
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerabilityLia Gore, Sant Chawla, Antonio Petrilli, et al.Journal of the National Cancer Institute|March 26, 2026
FDA approvals for pediatric cancer indications using children's oncology group associated trials dataMargaret E Macy, Elizabeth Fox, Brenda J Weigel, et al.American Journal of Hematology|June 4, 2014
Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemiaLori A Gardner, Jelena Klawitter, Mark A Gregory, et al.Investigational New Drugs|September 21, 2011
Phase I combination study of trabectedin and capecitabine in patients with advanced malignanciesLia Gore, E Rivera, M Basche, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumorsRazelle Kurzrock, Amita Patnaik, Joseph Aisner, et al.European Journal of Cancer (Oxford, England : 1990)|November 4, 2017
Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanomaBirgit Geoerger, Christophe Bergeron, Lia Gore, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2025
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional ChondrosarcomaWilliam D Tap, Gregory M Cote, Howard Burris, et al.Annals of Surgical Oncology|September 10, 2017
Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase InhibitorVictor Manuel Villalobos, Francis Hall, Antonio Jimeno, et al.American Journal of Hematology|November 6, 2018
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American expertsNicholas J Short, Elias Jabbour, Maher Albitar, et al.Nature Communications|September 14, 2018
Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromesBrett M Stevens, Nabilah Khan, Angelo D'Alessandro, et al.Pageof 15